Vol. 4 No. 6 (2024): June
Reimbursement Recommendations

Bimekizumab (Bimzelx)

Published June 4, 2024

Key Messages

  • CADTH recommends that bimekizumab (Bimzelx) should be reimbursed by public drug plans for the treatment of adult patients with active ankylosing spondylitis (AS) who have responded inadequately or are intolerant to conventional therapy if certain conditions are met.
  • Bimzelx should only be covered to treat adult patients with active AS based on the criteria used by each public drug plan for reimbursement of biologic disease-modifying antirheumatic drugs (bDMARDs).
  • Bimzelx should only be reimbursed if prescribed by a rheumatologist or a clinician with experience in the treatment of adult patients with active AS who are not undergoing treatment with other bDMARDs or targeted synthetic DMARDs. The cost of Bimzelx should not exceed the least expensive bDMARD reimbursed for treating AS.